PHAXIAM Therapeutics S.A. (PHXM) NASDAQ

Currency In USD

PHAXIAM Therapeutics S.A.

Address

60 Avenue Rockefeller

Lyon, 69008

France

Phone

33 4 78 74 44 38

Website

https://www.erytech.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

October 26, 2017

Key Executives

Name	Title	Pay	Year Born
Jérôme Bailly	Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer & Qualified Person	270,978	1979
Eric Soyer	Deputy Chief Executive Officer, Deputy GM, Chief Financial Officer & Chief Operating Officer	415,056	1966
Thibaut du Fayet	Chief Executive Officer	0	1968
Philip L. Lorenzi	Consultant & Member of Scientific Board	0	N/A
Céline Breda	Chief Technology Officer	0	1971
Cindy Fevre	Chief Scientific Officer	0	N/A
Frederique Vieville	Chief Regulatory Officer	0	N/A
Karine Charton	Chief Business Officer	0	N/A
Naomi Eichenbaum	Director Investor Relations	0	N/A
Pascal Birman	Chief Medical Officer	0	N/A
Anne-Cécile Fumey	Vice President of Human Resources	0	1976

Description

PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, which is currently undergoing Phase 3 clinical trials for advanced pancreatic cancer (second-line treatment) and Phase 2 studies for triple-negative breast cancer and relapsed acute lymphoblastic leukemia. Additionally, PHAXIAM is advancing a range of phage-based therapies designed to combat severe, drug-resistant bacteria. These pathogens are responsible for over two-thirds of nosocomial (hospital-acquired) infections that resist conventional treatments, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Established in 2004 and headquartered in Lyon, France, the company was previously known as ERYTECH Pharma S.A. before adopting its current name, PHAXIAM Therapeutics S.A., in June 2023.